Front-Line Management of Mantle Cell Lymphoma in Canada: A Practical, Risk-Adapted Approach

Abstract

Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma (NHL) that accounts for approximately 5–7% of all lymphomas.1 Its clinical presentation is heterogeneous, ranging from an indolent leukemic non-nodal subtype that may be managed with observation to highly aggressive disease characterized by TP53 alterations, blastoid or pleomorphic morphology, and high Ki-67 expression. Although relatively uncommon, an estimated 500–600 new cases are diagnosed annually in Canada,2 underscoring the importance of optimizing evidence-based management strategies. In this review, we discuss front-line treatment approaches for MCL within the Canadian practice landscape.